Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

INDUSTRY 4 OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 11 Gastrointestinal 11 Gynecologic 8 Other hematologic neoplasm 6 Breast 6 Thoracic 5 Lymphoid 5 Genitourinary 5 Dermatologic 5 Head & Neck 4 Plasma cell 3 Other solid neoplasm 3 Sarcoma 2 Classical hematology 2 CNS 2 NET 1 Myeloid 1 Endocrine 1

Conditions

Intestinal Neuroendocrine Tumor 1

Interventions

lutetium Lu 177 dotatate 36 Everolimus 32 pembrolizumab 24 Temozolomide 21 Magnetic Resonance Spectroscopy 21 Nivolumab 18 lenvatinib 17 gallium Ga 68 dotatate 16 cabozantinib 15 Cisplatin 15 lanreotide 14 3-Iodobenzylguanidine 14 Capecitabine 13 trametinib 12 dabrafenib 12 Bevacizumab 12 Octreotide 11 Surveys and Questionnaires 10 Surgical Procedures, Operative 10 Sunitinib 10 Radiosurgery 10 Positron Emission Tomography Computed Tomography 10 Blood Specimen Collection 10 Sorafenib 9 Paclitaxel 9 Ipilimumab 9 Carboplatin 9 surufatinib 8 Etoposide 8 Doxorubicin 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Data Collection × Endocrine × Clear all

NCT06876532 2025-11-18

LUTIBI

Institut Claudius Regaud

Phase NA Recruiting

Intestinal Neuroendocrine Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡